Pharmacodynamic and pharmacokinetic effects of MK-0343,a GABA A α 2,3 subtype selective agonist,compared to lorazepam and placebo in healthy male volunteers
Restricted accessOtherFirst published online January, 2008
Pharmacodynamic and pharmacokinetic effects of MK-0343,a GABA A α 2,3 subtype selective agonist,compared to lorazepam and placebo in healthy male volunteers
The use of non-selective γ-aminobutyric acid (GABA) enhancers, such as benzodiazepines in the treatment of anxiety disorders is still widespread but hampered by unfavourable side effects. some of these may be associated with binding properties to certain subtypes of the GABAA receptor that are unnecessary for therapeutic effects. MK-0343 was designed to be a less sedating anxiolytic, based on reduced efficacy at the α1 subtype and significant efficacy at α2 and α3 subtypes of the GABAA receptor.
This paper is a double-blind, four-way cross-over (n = 12) study to investigate the effects of MK-0343 (0.25 and 0.75 mg) in comparison to placebo and an anxiolytic dose (2 mg) of the non-selective agonist lorazepam. Effects were measured by eye movements, body sway, Visual Analogue scales (VAs) and memory tests.
Lorazepam impaired saccadic peak velocity (sPV), VAs alertness scores, postural stability and memory and increased saccadic latency and
inaccuracy. MK-0343 0.75 mg was equipotent with lorazepam as indicated by sPV (-42.4 deg/s), saccadic latency (0.02 s) and VAs alertness scores (1.50 ln mm), while effects on memory and postural stability were smaller. MK-0343 0.25 mg only affected postural stability to a similar extent as MK-0343 0.75 mg.
The effect profile of MK-0343 0.75 mg is different from the full agonist lorazepam, which could reflect the selective actions of this compound. Although less effect on VAs alertness was expected, diminished effects on memory and postural stability were present. Clinical studies in anxiety patients should show whether this dose of MK-0343 is therapeutically effective with a different side-effect profile.
Aldenkamp A.P., Vermeulen J., Alpherts W C J., Overweg J., van Parijs J A P., Verhoeff N P L G. (1992) Validity of computerized testing: patient dysfunction and complaints versus measured changes. In W E Dodson and M Kinsbourne (eds), Assessment of cognitive function, Demos, New York , pp. 51—68
2.
Allain H., Bentue-Ferrer D., Polard E., Akwa Y., Patat A. (2005) Postural instability and consequent falls and hip fractures associated with use of hypnotics in the elderly: a comparative review . Drugs Aging22: 749—765
3.
Alpherts W C J (1987) Computers as a technique for neurphysiological assessment in epilepsy. In Aldenkamp A P, Alpherts W C J, Meinardi H, Stores G (eds), Education and epilepsy, Swets & Zeitlinger, Lisse/Berwyn pp. 101—109
4.
Atack J.R. (2003) Anxioselective compounds acting at the GABA(A) receptor benzodiazepine binding site. Curr Drug Targets CNS Neurol Disord2: 213—232
5.
Atack J.R. (2005) The benzodiazepine binding site of GABA(A) receptors as a target for the development of novel anxiolytics. Expert Opin Investig Drugs14: 601—618
6.
Atack J.R., Hutson P.H., Collinson N., Marshall G., Bentley G., Moyes C., Cook S.M., Collins I., Wafford K., McKernan R.M., Dawson G.R. (2005) Anxiogenic properties of an inverse agonist selective for alpha3 subunit-containing GABA A receptors. Br J Pharmacol144: 357—366
7.
Atack J.R., Wafford K.A., Tye S.J., Cook S.M., Sohal B., Pike A., Sur C., Melillo D., Bristow L., Bromidge F., Ragan I., Kerby J., Street L., Carling R., Castro J.L., Whiting P., Dawson G.R., McKernan R.M. (2006) TPA023 [7-(1,1-Dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluor ophenyl)-1,2,4-triazolo[4,3-b]pyridazine], an Agonist Selective for {alpha}2- and {alpha}3-Containing GABAA Receptors, Is a Nonsedating Anxiolytic in Rodents and Primates. J Pharmacol Exp Ther316: 410—422
8.
Aufdembrinke B. (1998) Abecarnil, a new beta-carboline, in the treatment of anxiety disorders. Br J Psychiatry (Suppl.) 55—63
9.
Barbee J.G. (1993) Memory, benzodiazepines, and anxiety: integration of theoretical and clinical perspectives. J Clin Psychiatry54 (Suppl.) 86—97
10.
Bond A., Lader M. (1974) The use of analogue scales in rating subjective feelings. Br J Med Psychol47: 211—218
11.
Buffett-Jerrott S.E., Stewart S.H., Bird S., Teehan M.D. (1998) An examination of differences in the time course of oxazepam's effects on implicit vs explicit memory. J Psychopharmacol12: 338—347
12.
Carling R.W., Madin A., Guiblin A., Russell M.G., Moore K.W., Mitchinson A., Sohal B., Pike A., Cook S.M., Ragan I.C., McKernan R.M., Quirk K., Ferris P., Marshall G., Thompson S.A., Wafford K.A., Dawson G.R., Atack J.R., Harrison T., Castro J.L., Street L.J. (2005) 7-(1,1-Dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2- fluoro phenyl)-1,2,4-triazolo[4,3-b]pyridazine: a functionally selective gamma-aminobutyric acid(A) (GABA(A)) alpha2/alpha3-subtype selective agonist that exhibits potent anxiolytic activity but is not sedating in animal models. J Med Chem48: 7089—7092
13.
de Haas S.L., de Visser S.J., van der Post J.P., de smet M., Schoemaker R.C., rijnbeek B., Cohen A.F., Vega J.M., Agrawal N G B., Goel T.V., Simpson R.C., Pearson L.K., Li S., Hesney M M M G., Gerven J M Av (2007) Pharmacodynamic and pharmacokinetic effects of TPA023, an alpha2,3 subtype selective agonist, compared to lorazepam and placebo in healthy volunteers. Accepted for publication in J Psychopharmacol21: 374—383
14.
de Visser S.J., van der Post J.P., de Waal P.P., Cornet F., Cohen A.F., van Gerven J.M. (2003) Biomarkers for the effects of benzodiazepines in healthy volunteers. Br J Clin Pharmacol55: 39—50
15.
Dias R., Sheppard W.F., Fradley R.L., Garrett E.M., Stanley J.L., Tye S.J., Goodacre S., Lincoln R.J., Cook S.M., Conley R., Hallett D., Humphries A.C., Thompson S.A., Wafford K.A., Street L.J., Castro J.L., Whiting P.J., Rosahl T.W., Atack J.R., McKernan R.M., Dawson G.R., Reynolds D.S. (2005) Evidence for a significant role of alpha3-containing GABAA receptors in mediating the anxiolytic effects of benzodiazepines. J Neurosci25: 10682—10688
16.
Evans S.M., Foltin R.W., Levin F.R., Fischman M.W. (1995) Behavioral and subjective effects of DN-2327 (pazinaclone) and alprazolam in normal volunteers. Behav Pharmacol6: 176—186
17.
Green J.F., McElholm A., King D.J. (1996) A comparison of the sedative and amnestic effects of chlorpromazine and lorazepam. Psychopharmacology (Berl)128: 67—73
18.
Griebel G., Perrault G., Simiand J., Cohen C., Granger P., Decobert M., Francon D., Avenet P., Depoortere H., Tan S., Oblin A., Schoemaker H., Evanno Y., Sevrin M., George P., Scatton B. (2001) SL651498: an anxioselective compound with functional selectivity for alpha2- and alpha3-containing gamma-aminobutyric acid(A) (GABA(A)) receptors. J Pharmacol Exp Ther298: 753—768
19.
Griebel G., Perrault G., Simiand J., Cohen C., Granger P., Depoortere H., Francon D., Avenet P., Schoemaker H., Evanno Y., Sevrin M., George P., Scatton B. (2003) SL651498, a GABAA receptor agonist with subtypeselective efficacy, as a potential treatment for generalized anxiety disorder and muscle spasms. CNS Drug Rev9: 3—20
20.
Izaute M., Bacon E. (2005) Specific effects of an amnesic drug: effect of lorazepam on study time allocation and on judgment of learning. Neuropsychopharmacology30: 196—204
21.
Johnstone T.B., Hogenkamp D.J., Coyne L., Su J., Halliwell R.F., Tran M.B., Yoshimura R.F., Li W.Y., Wang J., Gee K.W. (2004) Modifying quinolone antibiotics yields new anxiolytics . Nat Med10: 31—32
22.
Langen B., Egerland U., Bernoster K., Dost R., Unverferth K., Rundfeldt C. (2005) Characterization in rats of the anxiolytic potential of ELB139 [1-(4-chlorophenyl)-4-piperidin-1-yl-1,5-dihydro-imidazol-2-on], a new agonist at the benzodiazepine binding site of the GABAA receptor. J Pharmacol Exp Ther314: 717—724
23.
Licata S.C., Platt D.M., Cook J.M., Sarma P.V., Griebel G., Rowlett J.K. (2005) Contribution of GABAA receptor subtypes to the anxiolytic-like, motor, and discriminative stimulus effects of benzodiazepines: studies with the functionally selective ligand SL651498 [6-fluoro-9-methyl-2-phenyl-4-(pyrrolidin-1-yl-carbonyl)-2,9-dihydro-1H-py ridol[3,4-b]indol-1-one]. J Pharmacol Exp Ther313: 1118—1125
24.
Lippa A., Czobor P., Stark J., Beer B., Kostakis E., Gravielle M., Bandyopadhyay S., Russek S.J., Gibbs T.T., Farb D.H., Skolnick P. (2005) Selective anxiolysis produced by ocinaplon, a GABA(A) receptor modulator. Proc Natl Acad Sci USA102: 7380—7385
25.
Low K., Crestani F., Keist R., Benke D., Brunig I., Benson J.A., Fritschy J.M., Rulicke T., Bluethmann H., Mohler H., Rudolph U. (2000) Molecular and neuronal substrate for the selective attenuation of anxiety. Science290: 131—134
26.
Mattila M.J., Vanakoski J., Kalska H., Seppala T. (1998) Effects of alcohol, zolpidem, and some other sedatives and hypnotics on human performance and memory. Pharmacol Biochem Behav59: 917—923
27.
McKernan R.M., Rosahl T.W., Reynolds D.S., Sur C., Wafford K.A., Atack J.R., Farrar S., Myers J., Cook G., Ferris P., Garrett L., Bristow L., Marshall G., Macaulay A., Brown N., Howell O., Moore K.W., Carling R.W., Street L.J., Castro J.L., Ragan C.I., Dawson G.R., Whiting P.J. (2000) Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABA(A) receptor alpha1 subtype. Nat Neurosci3: 587—592
28.
Micallef J., Soubrouillard C., Guet F., Le Guern M.E., Alquier C., Bruguerolle B., Blin O. ( 2001) A double blind parallel group placebo controlled comparison of sedative and amnesic effects of etifoxine and lorazepam in healthy subjects . Fundam Clin Pharmacol15: 209—216
29.
Mohler H., Crestani F., Rudolph U. (2001) GABA(A)-receptor subtypes: a new pharmacology. Curr Opin Pharmacol1: 22—25
30.
Nelson R.E., Dickson A.L., Banos J.H. (2000) An automated administration of Corsi's Block-tapping Test. Percept Mot Skills91: 578—580
31.
Norris H. (1971) The action of sedatives on brain stem oculomotor systems in man. Neuropharmacology10: 181—191
Patat A., Foulhoux P. (1985) Effect on postural sway of various benzodiazepine tranquillizers. Br J Clin Pharmacol20: 9—16
34.
Rudolph U., Crestani F., Benke D., Brunig I., Benson J.A., Fritschy J.M., Martin J.R., Bluethmann H., Mohler H. (1999) Benzodiazepine actions mediated by specific gamma-aminobutyric acid(A) receptor subtypes. Nature401: 796—800
35.
Rudolph U., Crestani F., Mohler H. (2001) GABA(A) receptor subtypes: dissecting their pharmacological functions. Trends Pharmacol Sci22: 188—194
36.
Scott-Stevens P., Atack J.R., Sohal B., Worboys P. (2005) Rodent pharmacokinetics and receptor occupancy of the GABAA receptor subtype selective benzodiazepine site ligand L-838417 . Biopharm Drug Dispos26: 13—20
37.
Tobler I., Kopp C., Deboer T., Rudolph U. (2001) Diazepam-induced changes in sleep: role of the alpha 1 GABA(A) receptor subtype. Proc Natl Acad Sci USA98: 6464—6469
38.
van Steveninck A.L., Cohen A.F., Ward T. ( 1989) A microcomputer based system for recording and analysis of smooth pursuit and saccadic eye movements. Br J Clin Pharmacol27: 712P—713P
39.
van Steveninck A.L., Schoemaker H.C., Pieters M.S., Kroon R., Breimer D.D., Cohen A.F. (1991) A comparison of the sensitivities of adaptive tracking, eye movement analysis and visual analog lines to the effects of incremental doses of temazepam in healthy volunteers. Clin Pharmacol Ther50: 172—180
40.
van Steveninck A.L., Verver S., Schoemaker H.C., Pieters M.S., Kroon R., Breimer D.D., Cohen A.F. (1992) Effects of temazepam on saccadic eye movements: concentration-effect relationships in individual volunteers. Clin Pharmacol Ther52: 402—408
41.
van Steveninck A.L., Gieschke R., Schoemaker H.C., Pieters M.S., Kroon J.M., Breimer D D.D., Cohen A.F. (1993) Pharmacodynamic interactions of diazepam and intravenous alcohol at pseudo steady state. Psychopharmacology (Berl)110: 471—478
42.
van Steveninck A.L., Gieschke R., Schoemaker R.C., Roncari G., Tuk B., Pieters M.S., Breimer D.D., Cohen A.F. (1996) Pharmacokinetic and pharmacodynamic interactions of bretazenil and diazepam with alcohol. Br J Clin Pharmacol41: 565—573
43.
Whiting P.J. (2006) GABA-A receptors: a viable target for novel anxiolytics?Curr Opin Pharmacol6: 24—29
44.
Wright B.M. (1971) A simple mechanical ataxia-meter. J Physiol218: 27P—28P
